

# Saudi Arabia

Population 2016

32 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.84 (0.64–1.1)	2.6 (2–3.3)
Mortality (HIV+TB only)	0.013 (<0.01–0.017)	0.04 (0.03–0.05)
Incidence (includes HIV+TB)	3.3 (2.9–3.9)	10 (8.9–12)
Incidence (HIV+TB only)	0.079 (0.066–0.094)	0.25 (0.2–0.29)
Incidence (MDR/RR-TB)**	0.13 (0.11–0.16)	0.41 (0.33–0.48)

Estimated TB incidence by age and sex (thousands)*, 2016			
	0-14 years	> 14 years	Total
Females	0.16 (0.14–0.19)	0.97 (0.82–1.1)	1.1 (0.96–1.3)
Males	0.18 (0.16–0.21)	2 (1.7–2.3)	2.2 (1.9–2.6)
Total	0.34 (0.29–0.4)	3 (2.6–3.5)	3.3 (2.9–3.9)

TB case notifications, 2016	
Total cases notified	3 004
Total new and relapse	2 913
- % tested with rapid diagnostics at time of diagnosis	25%
- % with known HIV status	65%
- % pulmonary	74%
- % bacteriologically confirmed among pulmonary	84%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.26 (0.19–0.34)

TB/HIV care in new and relapse TB patients, 2016		
	Number	(%)
Patients with known HIV-status who are HIV-positive	45	2%
- on antiretroviral therapy	43	96%

Drug-resistant TB care, 2016			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			94 (76–110)
Estimated % of TB cases with MDR/RR-TB	2.6% (2–3.2)	20% (14–26)	
% notified tested for rifampicin resistance	49%	60%	1 507
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 46, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 34, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2015	72%	3 309
Previously treated cases, excluding relapse, registered in 2015	44%	120
HIV-positive TB cases registered in 2015	45%	69
MDR/RR-TB cases started on second-line treatment in 2014	27%	55
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	3%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2017	
National TB budget (US\$ millions)	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB